Annexon (ANNX) Cash from Operations (2019 - 2026)
Annexon (ANNX) posted quarterly Cash from Operations of 46796000.0 for Q1 2026, up 6.51% year-over-year from 43935434.97 in Q1 2025, and down 1.89% quarter-over-quarter from 45926000.0 in Q4 2025.
Powered by 
Analysis
Annexon (ANNX) Cash from Operations (2019 - 2026) Analysis & Trends
Annexon's Cash from Operations history runs 8 years deep, the most recent figure standing at 46796000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 6.51% year-over-year to 46796000.0; the TTM figure through Mar 2026 stood at 183097000.0 (down 30.98% YoY), while the FY2025 annual figure was 186356000.0, down 57.92% from the prior year.
- Cash from Operations for Q1 2026 stood at 46796000.0, down from 45926000.0 in the prior quarter.
- The five-year high for Cash from Operations was 21709000.0 in Q2 2024, with the low at 52304000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 32015000.0 (2024), against an average of 34624058.82.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 40.33% in 2024, then plunged 77.08% in 2025.
- Annexon's Cash from Operations stood at 27139000.0 in 2022, then climbed by 13.49% to 23477000.0 in 2023, then plunged by 53.41% to 36015000.0 in 2024, then slipped by 27.52% to 45926000.0 in 2025, then slipped by 1.89% to 46796000.0 in 2026.
- Business Quant data shows ANNX's Cash from Operations at 46796000.0 in Q1 2026, 45926000.0 in Q4 2025, and 52304000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Annexon | 976.88 Mn | 976.88 Mn | - | -48.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.01 Mn |
| Mar 31, 2026 | -46.80 Mn |
| Dec 31, 2025 | -45.93 Mn |
| Sep 30, 2025 | -52.30 Mn |
| Jun 30, 2025 | -38.07 Mn |
| Mar 31, 2025 | -50.06 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Sep 30, 2024 | -32.02 Mn |
| Jun 30, 2024 | -21.71 Mn |
| Mar 31, 2024 | -28.27 Mn |
| Dec 31, 2023 | -23.48 Mn |
| Sep 30, 2023 | -28.29 Mn |
| Jun 30, 2023 | -36.38 Mn |
| Mar 31, 2023 | -32.99 Mn |
| Dec 31, 2022 | -27.14 Mn |
| Sep 30, 2022 | -30.72 Mn |
| Jun 30, 2022 | -28.16 Mn |
| Mar 31, 2022 | -30.29 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -29.72 Mn |